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The survival of tumour cells in a new tissue environment is crucial for tumour metastasis. Factors contributing to the death of
tumour cells during metastasis are not completely understood. In murine melanoma model, activation of Fas (CD95, APO-1)
signal in tumour cells reduces their lung metastasis potential, which may be associated with an induction of apoptosis in
tumours. To elucidate the cellular mechanism, we used a Fas-ligand (Fas-L) speciﬁc ribozyme (Fas-L
ribozyme) to suppress the
expression of Fas-L but not Fas or TNF-a in B16F10 melanoma cells. The Fas-L
ribozyme-carrying cells grew slightly faster in vitro
with better viability than controls. Suppression of Fas-L in B16F10 melanoma cells by Fas-L
ribozyme enhanced lung metastasis of
the cells in C57BL/6 mice, and that was correlated with reductions in both apoptotic tumour cells and granulocytic inﬁltration.
Mice depleted of granulocytes, but not CD4
+ and CD8
+ cells, showed a greatly elevated susceptibility to lung metastasis.
Moreover, apoptosis in tumour cells was signiﬁcantly reduced in granulocyte-depleted mice during the course of tumour
formation. Taken together, our ﬁndings indicate that Fas-L-associated apoptosis in tumour cells determines the metastasis
behaviour of melanoma in the lung and this apoptosis is primarily mediated by the cytotoxicity of recruited granulocytes.
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Apoptosis which occurs in tumour cells during or just after extravasa-
tion from blood vessel into a new tissue environment is a crucial step
in metastasis (Walsh and Sata, 1999). Apoptotic factors of tumours
contributing to metastatic tumour behaviour are not completely
understood. Among the candidate apoptotic signals, the Fas (also
named as CD95, APO-1)/Fas-ligand (Fas-L) system plays important
roles in organ homeostasis and immune surveillance against tumours
(Walker et al, 1998). Fas-L is a member of the tumour necrosis factor
receptor superfamily and triggers a death signal into Fas-bearing cells
after engagement with Fas molecule (Itoh et al, 1991; Takahashi et al,
1994). Functional expression of Fas-L in melanoma has been demon-
strated in vitro (Hahne et al, 1996). During the progression of human
melanoma, tumour Fas-L increases gradually (Terheyden et al, 1999;
Soubraneetal,2000).However,theﬁndingthattheFas/Fas-Linterac-
tion suppressed lung metastasis of melanoma in murine models
argued against a major contribution of tumour Fas-L in escape from
immune surveillance (Owen-Schaub et al, 1998; Rivoltini et al,
1998; Sprecher et al, 1999) and suggested a negative role of Fas-asso-
ciated apoptosis in metastasis. In addition, ectopic expression of
Fas-L in transgenic animals or tumours revealed that Fas-L enhanced
neutrophil recruitment and mediated destruction of certain Fas-L-
positive cells (Arai et al, 1997; Chervonsky et al, 1997; Seino et al,
1997; O’Flaherty et al, 1998). At moment, it is not known whether
the Fas-L-associated suppression in metastasis is mediated by trigger-
ing the suicidal apoptotic Fas signal in tumour cells or by an indirect
action through the recruited inﬂammatory cells.
In this study, we investigated the contribution of immune cells to
Fas-associated apoptosis in tumours. We used a hammerhead Fas-L-
speciﬁc ribozyme (Fas-L
ribozyme) to suppress the Fas-L gene (Yang et
al, 1999; Chio et al, 2001). The Fas-L
ribozyme effectively inhibited the
expression of Fas-L in melanoma cells at both mRNA and protein
levels. Stable transfectants carrying Fas-L
ribozyme were established to
evaluate the contribution of tumour Fas-L to cell growth, apoptosis,
and lung metastasis. The involvement of immune cells in the
processes of lung metastasis was explored by cell depletions using
antibodies for CD4-, CD8-cells or granulocytes. Our results clearly
demonstrate that granulocytes play a crucial role in the Fas-L-asso-
ciated apoptosis during lung metastasis.
MATERIALS AND METHODS
Cell culture
The melanoma cell line B16F10, kindly provided by Dr Shiau Al,
NCKU, is derived from a spontaneous melanoma in C57BL/6
mouse and has lung metastasis ability (Mackensen et al, 1993).
Tumour cells were cultured in DMEM medium (Life Technologies,
Grand Island, NY, USA) supplemented with 10% foetal calf serum
(FCS) and 2 mML -glutamine at 5% CO2/378C in a humidiﬁed
atmosphere. Cell growth rate was determined. In brief, 2.5610
4
of cells in a 60 mm-dish were at ﬁrst starved in 0.1% FCS/DMEM
for 24 h, and then re-grew in a regular 10% FCS/DMEM. Cells
were harvested at intervals to determine the number of viable cells
by Trypan blue exclusion method.
DNA transfection and selection of stable cells
The sequences of the oligonucleotides used to construct Fas-L
ribo-
zyme were as follow: sense sequence: 5'-ATGAATTCCCGGAA-
GTACTGATGAGTCGTGATACGACGAAACTTTGGATCCCGA-3';
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www.bjcancer.comantisense sequence: 5'-TCGGGATCCAAAGTTTCGCGTATCAC-
GACTCATCAGTACTTCCGGGAATTCAT-3'. The ribozyme was
directly linked to upstream of the EGFP gene in pEGFP-N1 plas-
mid (CLONTEC, Palo Alto, CA, USA) to form a fusion
transcript (Chio et al, 2001). Plasmid DNA was delivered into cells
using the lipofection method with a ratio of 5 mg DNA per 30 ml
lipofectamine (Qiagen, Hilden, Germany). Cells transfected with
pEGFP-N1 plasmid served as the vector control. After DNA trans-
fection, cells were grown in regular 10% FCS/DMEM for 48 h and
then selected with geneticin (G418 sulphate, Gibco, Darmstadt,
Germany) at an effective concentration of 1.5 mg ml
71. Bulk
culture or stable clones were established for at least 3 months
before they were subjected to further study.
Semi-quantitative reversed transcription-polymerase chain
reaction (RT–PCR)
Total RNA was puriﬁed using the RNeasy Kit according to the
manufacturer’s instruction (Qiagen) and converted to cDNA by
StrataScrip
TM-H-reverse transcriptase with oligo-dT primer in the
presence of RNasin (Stratagen, CA, USA). RT–PCR for Fas-L,
Fas, TNF-a and b-actin were performed as described previously
(Hahne et al, 1996; Yang et al, 1999). The cDNA generated was
subjected to 25–35 cycles of PCR ampliﬁcation on a DNA Ther-
mal Cycler (Hybaid Omnigene, Middlesex, UK). b-Actin served
as a quantitative control for PCR. PCR products were fractionated
by agarose electrophoresis, stained with ethidium bromide, and
visualised under UV light.
Western blot
Cells were extracted with a buffer containing 20 mM Tris, 150 mM
NaCl, 1 mM EDTA, 1% Nonidet P-40, 1 mM PMSF and
0.1 U ml
71 leupeptin. Proteins were separated in SDS-polyacryla-
mide gel and electroblotted onto polyvinyl diﬂuoride membrane
(MSI, Westboro, MO, USA). The proteins bounded on the
membrane were probed with the mouse antibody (Ab)-recognising
Fas-L (clone33; Transduction Laboratories, Lexington, KY, USA)
followed by a sheep anti-mouse IgG conjugated with horseradish
peroxidase (Dako Corp., Carpinteria, CA, USA). The Fas-L band
was made visible by ﬂuorography with enhanced chemiluminescence
detection kit (Amersham/Pharmacia Biotech., UK). Duplicate blot
was probed with a-tubulin-speciﬁc Ab (clone DM1A; NeoMarker,
Fremont, CA, USA) and served as protein-loading control.
Tumour formation and immunohistochemical staining
Eight-week-old C57BL/6 mice (H2
b) were purchased from the
National Laboratory Animal Breeding and Research Center, Taiwan,
R.O.C. and maintained under speciﬁc pathogen-free condition. All
animal experiments have been carried out with approval of the ethi-
cal committee of Animal Research Center, National Cheng-Kung
University. The ethical guidelines that were followed meet the stan-
dards required by the UKCCCR guidelines (Workman et al, 1998).
To investigate lung metastasis, mice received 0.5–5610
5 of tumour
cells in 0.1 ml PBS via the tail vein injection (i.v. injection). Meta-
static lung tumours in mice were assessed under a dissecting
microscopy. Organs were surgically obtained, ﬁxed in 10% buffered
formalin solution for parafﬁn block preparation or for ﬂash-frozen
in O.C.T. embedding medium (Miles Inc., Elkhart, IN, USA). Five-
mM tissue sections were placed on poly-L-lysine-coated glass slides,
ﬁxed with 3.7% paraformaldehyde, and treated with 3% H2O2. Cells
were stained with rat anti-NK mAb (DX5), rat anti-CD4 mAb
(H129.19), rat anti-CD8 mAb (53-6.7) (PharMingen, San Diego,
CA, USA), rat anti-granulocyte mAb (RB6-8C5), rabbit anti-Fas
Ab (M-20) or rabbit anti-Fas ligand Ab (N-20) (Santa Cruz Biotech-
nology, CA, USA). Appropriate sheep anti-rat IgG or goat anti-
rabbit IgG conjugated with peroxidase (Boehringer Manheim
GmbH, Mannheim, Germany) was used as secondary antibodies.
Peroxidase staining was developed by aminoethyl carbazole
substrate kit (Zymed, San Francisco, CA, USA) and showed
reddish-brown colour. Sections were counterstained with haematox-
ylin and mounted with glycerol gelatin.
Detection of apoptotic cells in culture
Apoptotic cells become susceptible to merocyanine 540 (MC540,
Sigma, St. Louis, MO, USA) binding due to alteration of surface
membrane and can be detected by ﬂow cytometric analysis (Reid
et al, 1996; Yang et al, 1999). To stain apoptotic cells, cells of 3-
day-old culture were harvested, suspended in PBS containing
0.1% BSA and stained with 1 mg ml
71 MC540 for 10 min in
the dark. Subsequently, cells were washed once with PBS and
subjected to ﬂow cytometric analysis (FACScan, Becton Dickinson,
Mountain View, CA, USA) with a gate set to examine a total of
10
4 cells. Apoptotic cells in tumour nodules were detected by
TUNEL labelling detecting free 3'-OH groups in fragmented
DNA in situ (ApopTag-peroxidase in situ apoptosis detection kit,
Oncor, MD, USA). Parafﬁn-embedded, slide-mounted tissue
sections were deparafﬁnised and treated with proteinase K followed
by 3% H2O2. After nick end labelling with digoxigenin-deoxyuri-
dine triphosphate by terminal deoxynucleotidyl transferase,
immunostaining was performed using peroxidase-conjugated anti-
digoxigenin Ab. Apoptotic cells were visualised with diaminobenzi-
dine substrate and became brown colour.
Depletion of CD4
+, CD8
+ cells and granulocytes
Ascitic ﬂuids were generated from hybridomas GK1.5, 2.43 and
RB6-8C5 secreting rat monoclonal antibodies for antibodies against
mouse CD4, CD8 and granulocyte marker (Ly-6G), respectively
(Staats et al, 1991; Tumpey et al, 1996). The CD4- and CD8-speciﬁc
Abs were further puriﬁed by afﬁnity chromatography on a protein
G-sepharose column (Pharmacia, LKB Biotechnology, Piscataway,
NJ, USA) and adjusted to a ﬁnal concentration of 3 mg ml
71.
Protocols modiﬁed from Staats et al (1991) was used to deplete
CD4
+ or CD8
+ cells, so mice were given 100 mg anti-CD4 or anti-
CD8 Ab by intraperitoneal (i.p.) injection on day 72. Booster
anti-CD4 or anti-CD8 Ab was given twice on days 7 and 14. Deple-
tion of granulocytes was achieved by a serial of i.p. injections with
anti-granulocyte Ab according to a modiﬁed protocol as previously
reported (Tumpey et al, 1996) as follows: 100 mlo n75 h; 100 mlo n
day 3; 150 ml on day 5; 200 ml on days 7 and 9; 250 ml on days 12
and 15. Control mice received puriﬁed rat IgG (ICN, Pharmaceuti-
cals Inc. Cappel, OH, USA) following similar protocol. Spleen cells
were stained with anti-CD4 (H129.19, FITC-conjugated; PharMin-
gen) or anti-CD8 (53-6.7, PE conjugated; PharMingen) on days 6
or 18 to determine the extent of T cell depletion. Reduced number
of granulocytes in peripheral blood in granulocyte-depleted mice
was also conﬁrmed on days 6 or 18 by ﬂow cytometric analysis using
FITC-conjugated antibody (RB6-8C5; PharMingen).
Statistic analysis
Results were analysed by Student’s t-test. Differences with P50.05
were judged as signiﬁcant.
RESULTS
Fas-L
ribozyme-carrying cells
After DNA transfection followed by antibiotic selection, bulk
cultures and randomly chosen cell clones were established. Most
of those stable clones emitted green ﬂuorescence under UV light
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carrying pEGFP-N1 plasmid were named V for bulk culture and
Vn for stable clones; cells carrying Fas-L
ribozyme plasmid were
named R for bulk culture and Rn for stable clones. Rn, Fas-L
ribo-
zyme-carrying clones, showed reduced expression of Fas-L to
various extents both at transcriptional and translational levels
(Figure 1a,b). Fas-L
ribozyme did not affect the expressions of Fas
and TNF-a in melanoma cells. Along with a reduction in Fas-L
protein, most of those Rn cells grew slightly faster in vitro than
Vn, cells carrying pEGFP-N1 control plasmid, did (Figure 2). We
further measured the spontaneous apoptosis in 3-day cultures,
which presumably had more Fas/Fas-L engagement due to cell–cell
contact in relatively conﬂuent growth. In comparison with the
enhanced growth rate, less apoptosis was observed in Rn than
Vn as detected by MC-540 staining (Figure 3).
Effect of Fas-L
ribozyme on lung metastasis
Bulk cultures and several established cell clones have been used to
evaluate the contribution of tumour Fas-L to lung metastasis in
C57BL/6 mice. Mice began to develop grossly observable tumour
nodules in the lung around 14–18 days after inoculation with
1610
5 of parental B16F10 cells. Similarly, metastatic tumour
nodules were observed in mice who received stable cells of Vn,
bulk culture or clones, at day 14 post-inoculation (Table 1). Rn
produced more lung tumour nodules in mice than Vn did after
day 14 post-inoculation (Figure 4). Tumour cells accumulated ﬁrst
in alveoli (day 7) and then expanded to alveolar sacs or near blood
vessels (after 14 days).
CD4
+-, CD8
+ cells- and granulocyte-depletion
To explore the anti-tumour effect of immune cells in vivo, CD4
+,
CD8
+ cells and granulocytes in mice were depleted by antibodies.
The extents of depletions for CD4
+ and CD8
+ cells in the spleen
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Figure 1 Decreased expression of Fas-L in Fas-L
ribozyme-carrying cells.
After transfection, cells were selected in geneticin-containing medium for
3 months. RT–PCR and Western blot analysis were performed as de-
scribed in Materials and Methods. (A) The densities of ethidium bro-
mide-stained RT–PCR products corresponding to Fas-L and b-actin
were quantiﬁed by a densitometer. The ratio of Fas-L over b-actin repre-
sents the Fas-L expression in individual clones. The inserted photograph
shows representative gels for RT–PCR-ampliﬁed products of Fas-L, Fas,
TNF-a and b-actin. (B) The densities of protein bands corresponding to
Fas-L and a-tubulin were quantiﬁed by a densitometer. The ratio of Fas-
L over a-tubulin represents the amount of Fas-L level in individual clones.
Representative Western blot presented in inserted photograph shows
the expressions of Fas-L and a-tubulin. Vn: cells carrying pEGFP-N1 con-
trol plasmid; Rn: Fas-
ribozyme-carrying cell clones; P: parental B16F10 cells.
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Figure 2 Growth rate of cells with or without Fas-L
ribozyme. About
5610
4 cells were grown in regular 10% FCS/DMEM for 72 h. Cell num-
ber was then counted. Clones carrying EGFP-N1 plasmid (Vn); clones car-
rying Fas-L
ribozyme (Rn). Data represent means+s.d. of three independent
experiments.
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Figure 3 Apoptosis in 3-days culture of cells with or without
Fas-L
ribozyme. Cells, with (Rn) or without (Vn) Fas-L
ribozyme, were grown
in 10% FCS/DMEM for 72 h. Apoptotic cells were stained by MC540.
Cells with FL24230 were judged as MC540-positve and apoptotic. Data
represent means+s.d. of three independent experiments.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(3), 359–365were more than 90% (Figure 5A,B). After depletion by RB6-8C5
antibody, the number of granulocytes in peripheral blood reduced
to about 30% (Figure 5C). Figure 6 summarised the effects of
CD4
+-, CD8
+ cells- or granulocyte-depletion on lung metastasis.
Mice depleted of granulocytes showed an elevated susceptibility
to lung metastasis (Figure 6). Particularly, the incidence of lung
metastasis of controls in granulocytes-depleted mice at day 18
post-inoculation reached a degree similar to that of Rn in
immune-competent mice. CD4
+- or CD8
+ cells-depletion did not
affect, or even slightly suppress, lung metastasis of vector controls.
Among the Fas-L
ribozyme-carrying clones, R4 cells generated the
highest number of lung tumour nodules in this study and its meta-
static ability was not further increased in mice receiving antibodies
against CD4
+- CD8
+ cells- or granulocytes.
Immunohistochemical studies on the expression of Fas-L,
tumour inﬁltrating cells and apoptosis in tumours
A reduced expression of Fas-L was immunohistochemically
detected in metastatic lung tumours of Rn compared to that of
Vn (Figure 7). Histological examination revealed that small tumour
cell mass were formed in the lung 96 h post-inoculation of tumour
cells. Parental and control melanoma cells accumulated around
terminal bronchioles, alveolar ducts or alveolar sacs. Rn accumu-
lated around pulmonary veins and bronchioles. Similar to
parental cells, the cell lines established in this study did not develop
tumours in organs including liver, kidney, and spleen by i.v. inocu-
lation at day 18 post-inoculation (data not shown).
Granulocytes accumulated in the lung very soon, within 48–
96 h (Table 2). Intensive granulocyte inﬁltration in the bronchioles,
alveoli and alveoli sacs was observed in mice inoculated by Vn
(Figure 8A). In tumour nodules formed after 14–18 days post-
inoculation, cell inﬁltration was reduced. A small number of inﬁl-
trating cells including CD4
+, CD8
+ and NK cells were scattered
near most tumour foci (data not shown). However, tumour foci
with some inﬁltrated cells mostly comprised granulocytes were also
seen (Figure 8C), although with low frequency. Fas-L
ribozyme
reduced signiﬁcantly the number of inﬁltrating granulocytes in
tumour nodules of 96 h and 18 days after cell inoculation (Figure
8B,D), but not the numbers of CD4
+, CD8
+ and NK cells.
Massive apoptotic cells were observed in the lung of mice
received Vn cells in 48–96 h (Figure 9A) post-inoculation. Apop-
tosis still occurred frequently in tumour nodules formed by Vn
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Table 1 Metastatic tumour nodules in the lung after i.v. injection
Groups
Average number of gross tumour
nodules/Nth day
Exp 1(5610
5 cells) 14th day
V3 8+2 (3/3)
R1 223+34 (3/3)
Exp 2 (5610
4 cells) 14th day 19th day
V1 ND*(0/4) ND*(0/2)
R5 11+4 (4/4) 22+11 (2/2)
Exp 3 (5610
4 cells) 18th day
V 3.3+1.5 (3/3)
V4 15.0+4.4 (3/3)
R 65.8+24.3 (4/4)
R6 85.7+7.0 (3/3)
Exp 4 (5610
4 cells) 14th day 18th day
V2 1+1 (3/3) 11.7+8.5 (6/6)
R4 112+55 (2/2) 314.5+104.0 (4/4)
R2 137.4+75.6 (5/5)
aNumber in paragraph is the number of tumour-bearing mice over total mice. *ND:
Although lung tumour nodules were not grossly observed, some tiny tumour cell
mass was seen in tissue section under light microscopy.
Figure 4 Tumour formation of cells with or without Fas-L
ribozyme in 8-
week-old C57BL/6 mice. Approximate 5610
4 stable cells, vector control
(V2; A) or Fas-L
ribozyme carrying cells (R4; B) were inoculated through tail
vein. Lung was harvested to observe tumour nodules at 14 days post-in-
oculation.
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Figure 5 CD4
+, CD8
+ cells or granulocytes in antibody-treated mice.
Spleenic CD4
+-( A), CD8
+ cells (B) or granulocytes (C) in circulating
blood of mice were stained with antibodies for CD4, CD8 or granulo-
cytes, respectively or control-Ig. Shown are representative dotplots.
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British Journal of Cancer (2002) 87(3), 359–365 ã 2002 Cancer Research UKafter 14 days post-inoculation (Figure 9C). Furthermore, quite a
few death cells in tumour nodules were morphologically tumour
origin and TUNEL-staining positive. Apoptosis was ameliorated
signiﬁcantly in tumour nodules of Rn (Figure 9B,D). We further
evaluated the apoptosis in granulocyte-depleted mice. Few cells
were TUNEL-positive in the tumour nodules obtained from gran-
ulocyte-depleted mice inoculated with Rn or Vn for 96 h (Figure
9E,F).
DISCUSSION
The application of Fas-L
ribozyme effectively and speciﬁcally
suppressed the expression of Fas-L in B16F10 cells as revealed by
RT–PCR, Western blot and immunohistochemistry. Transfectants
carrying Fas-L
ribozyme grew slightly faster in vitro with better viabi-
lity than vector controls. Since Fas-L
ribozyme did not alter the
expressions of Fas and TNF-a, a suppression of the Fas-L by
Fas-L
ribozyme resulting in less Fas/Fas-L ligation should account
for the reduced apoptosis in vitro. The suicidal destruction of
tumour cells has been reported in Fas signal-sensitive tumours after
transfer of Fas-L gene (Arai et al, 1997; Walker et al, 1998). In
addition, delivering Fas-L
ribozyme into human glioma or Ras-acti-
vated NIH3T3 malignant cell lines also reduced apoptosis in
those cells (Chio et al, 2001, our unpublished data). It seems that
the Fas/Fas-L suicidal effect could occur widely in different malig-
nant cells. Although a growth-promoting reverse signalling for
lymphocytes through Fas-L has been suspected (Suzuki and Fink,
1998), down-regulation of Fas-L in melanoma cells caused an
increase in growth rate in vitro indicating that Fas-L did not elicit
such reverse signalling in melanoma.
We then further evaluated the lung metastatic potential of Fas-
L
ribozyme-transfectants in C57/BL6 mice. Down regulation of Fas-L
by Fas-L
ribozyme drastically enhanced lung metastasis that was
correlated with reductions in both apoptotic tumour cells and
granulocytic inﬁltration. The recruitment of granulocytes in the
Fas-L-positive tumours can be attributed to the proinﬂammatory
effect of Fas-L that has been observed in several studies using ecto-
pic Fas-L expressing cells (Seino et al, 1997; Chen et al, 1998).
Alternatively, apoptotic body generated due to suicidal destruction
by itself has also been demonstrated to be a potent chemotactic
agent for cell recruitment (Horino et al, 1998). When phagocytes
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Figure 6 The formation of metastatic lung tumours in mice depleted for
CD4
+-, CD8
+-cells or granulocytes. Vn: vector controls; Rn: Fas-L
ribozyme-
carrying cells. Values shown are average of three independent experi-
ments. The numbers shown in parentheses over bars indicated the original
total number of lung tumour nodule. *P50.05; **P50.01.
Figure 7 Representative immunohistochemical staining of Fas-L protein
on tumour nodules. Lung tumour nodules of vector control (A)o r
Fas-L
ribozyme-carrying cells (B) were surgically obtained at 18 days post-in-
oculation and ﬁxed in 4% paraformaldehyde. Cryosection was immunos-
tained with antibody speciﬁc for Fas-L. Fas-L-positive cells show a
reddish-brown colour. Tumour cells of Vn were stained more intensively
than those of Rn.
Table 2 Granulocyte inﬁltration in the lung and tumour nodules
Time Vector (V13) Ribozyme (R6)
Lung sections Granulocytes/ﬁeld
a
48 h 9.9+5.9 1.8+1.1
96 h 8.7+3.6 2.0+1.1
Tumour nodules Granulocytes/nodule
b
18th day 10.7+8.6 1.3+2.0
aGranulocytes stained by anti-Ly-6G antibody in 30 random observation ﬁelds in the
lung;
bCells in 40 lung tumour nodules, that contained around 45–55 tumour cells
per nodule. Shown are mean+s.d.
Figure 8 Tumour inﬁltrating granulocytes. Tumour formation and tissue
preparation were performed as the procedures described in Figure 4.
Cryosections were immunostained with RB6-8C5 antibody recognising
granulocytes. Positive cells show a reddish-brown colour. (A and C) vec-
tor control; (B and D) Fas-L
ribozyme-carrying cells. (A and B): lung samples
of mice 96 h post-inoculation; (C and D) tumour nodules of 18 days post-
inoculation.
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(Chattergoon et al, 2000). In addition to granulocytes, a small
number of CD4
+, CD8
+, or NK cells were found near/around
the tumours, but the pattern of these cells was not affected by
Fas-L
ribozyme indicating that inﬁltration of these immune cells
involved other chemotatic signal.
It is noteworthy that the tumorogenic capacity of Vn cells did
not positively correlate with their absolute Fas-L amount suggest-
ing that a critical amount of Fas-L protein exists to fully
manifest the metastasis-inhibiting effect of Fas-L. When the
amount of Fas-L on tumour cells is above the threshold, the effect
of Fas-L reaches maximal. Only when the tumour Fas-L is in a
range below the threshold, a trend of dose-dependent inhibition
on lung metastasis of B16F10 was observable. For example, R4, a
clone expressing very low amounts of Fas-L protein, formed the
highest number of tumour nodules among all clones tested and
that could not be further enhanced by granulocyte depletion.
Besides, other uncharacterised factors may also contribute to
tumour metastasis, which would attenuate minor differences in
tumorigenicity between clones having litter difference in Fas-L
expression and diminish the expected dose effect. As mentioned
earlier, loss function of Fas has been linked to metastatic progres-
sion (Owen-Schaub et al, 1998). Similarly, we observed in this
study that lung metastasis was negatively correlated with the Fas/
Fas-L suicidal destruction occurred in melanoma cells in vitro
and the appearance of apoptotic cells in lung tumour nodules.
However, several lines of evidence showed that the autocrine suici-
dal Fas/Fas-L interaction was not the major limiting factor, at best
acted only as an initiator, for the Fas-L associated apoptosis in vivo
and for the reduced potential in metastasis. First, in the absence of
granulocytes, the expression of Fas-L on tumour did not inhibit
tumour metastasis. High Fas-L expressing cells, though showing
high apoptosis in vitro, could efﬁciently develop lung tumours in
granulocytes-depleted mice to a degree as Fas-L
ribozyme-carrying
cells did. Second, the apoptosis in tumour nodules obtained from
granulocyte-depleted mice was drastically reduced, evidence of a
granulocyte-dependant apoptosis in tumour. In these experiments,
the suicidal Fas/Fas-L signal in cells was not altered. Therefore,
tumour cell death is indeed a restriction factor for lung metastasis.
However, the death signal is not directly due to the suicidal Fas/
Fas-L signal. In addition, neutrophils isolated from peritoneal do
kill tumour cells in vitro, though with different efﬁciency depend-
ing on whether they carrying Fas-L
ribozyme or not (our unpublished
data). Thus, the recruited granulocytes mediate primarily the
destruction of metastatic tumour cells in the lung.
A pivotal role of cells of innate immunity in tumour combat
has previously been recognised in several tumours. The action
of tumour-suppressive Th1 cells through CpG DNA is granulo-
cyte-dependent (Egeter et al, 2000). Neutrophils, but not T
cells, mediate the primary rejection of Fas-L-overexpressing, Fas-
negative tumour cells in vivo (Seino et al, 1997). Our study
provides ﬁrm evidence for the anti-tumour effect of granulocytes
in lung metastasis. During the lung metastasis, T cells have few
impacts on tumour control. Depletions of CD4
+ or CD8
+ cells
did not affect (clone V3) or even slightly inhibit (clone V4) the
progression of tumours having high Fas-L. Recent studies have
also demonstrated that T cells speciﬁc for tumour antigens can
become actively tolerated during progression of tumours (Mack-
ensen et al, 1993; Adler et al, 1998). It is possible that altered
T cells may produce a distinct proﬁle of cytokine productions,
which in turn stimulate tumour formation (Medvedev et al,
1997; Mori et al, 1997).
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